Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

228 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma.
Cohen JB, Switchenko JM, Koff JL, Sinha R, Kaufman JL, Khoury HJ, Bumpers N, Colbert A, Hutchison-Rzepka A, Nastoupil LJ, Heffner LT, Langston AA, Lechowicz MJ, Lonial S, Flowers CR. Cohen JB, et al. Among authors: switchenko jm. Br J Haematol. 2015 Nov;171(4):539-46. doi: 10.1111/bjh.13637. Epub 2015 Aug 7. Br J Haematol. 2015. PMID: 26248505 Free PMC article. Clinical Trial.
Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma.
Nooka AK, Shanmugasundaram U, Cheedarla N, Verkerke H, Edara VV, Valanparambil R, Kaufman JL, Hofmeister CC, Joseph NS, Lonial S, Azeem M, Manalo J, Switchenko JM, Chang A, Linderman SL, Roback JD, Dhodapkar KM, Ahmed R, Suthar MS, Neish AS, Dhodapkar MV. Nooka AK, et al. Among authors: switchenko jm. J Clin Oncol. 2022 Sep 10;40(26):3057-3064. doi: 10.1200/JCO.21.02257. Epub 2022 Mar 8. J Clin Oncol. 2022. PMID: 35259002 Free PMC article.
Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia.
Chang A, Akhtar A, Linderman SL, Lai L, Orellana-Noia VM, Valanparambil R, Ahmed H, Zarnitsyna VI, McCook-Veal AA, Switchenko JM, Koff JL, Blum KA, Ayers AA, O'Leary CB, Churnetski MC, Sulaiman S, Kives M, Sheng P, Davis CW, Nooka AK, Antia R, Dhodapkar MV, Suthar MS, Cohen JB, Ahmed R. Chang A, et al. Among authors: switchenko jm. J Clin Oncol. 2022 Sep 10;40(26):3020-3031. doi: 10.1200/JCO.22.00088. Epub 2022 Apr 18. J Clin Oncol. 2022. PMID: 35436146 Free PMC article.
Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant.
Valanparambil RM, Carlisle J, Linderman SL, Akthar A, Millett RL, Lai L, Chang A, McCook-Veal AA, Switchenko J, Nasti TH, Saini M, Wieland A, Manning KE, Ellis M, Moore KM, Foster SL, Floyd K, Davis-Gardner ME, Edara VV, Patel M, Steur C, Nooka AK, Green F, Johns MA, O'Brein F, Shanmugasundaram U, Zarnitsyna VI, Ahmed H, Nyhoff LE, Mantus G, Garett M, Edupuganti S, Behra M, Antia R, Wrammert J, Suthar MS, Dhodapkar MV, Ramalingam S, Ahmed R. Valanparambil RM, et al. J Clin Oncol. 2022 Nov 20;40(33):3808-3816. doi: 10.1200/JCO.21.02986. Epub 2022 Jun 27. J Clin Oncol. 2022. PMID: 35759727 Free PMC article.
Impaired SARS-CoV-2 Variant Neutralization and CD8+ T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections.
Azeem MI, Nooka AK, Shanmugasundaram U, Cheedarla N, Potdar S, Manalo RJ, Moreno A, Switchenko JM, Cheedarla S, Doxie DB, Radzievski R, Ellis ML, Manning KE, Wali B, Valanparambil RM, Maples KT, Baymon E, Kaufman JL, Hofmeister CC, Joseph NS, Lonial S, Roback JD, Sette A, Ahmed R, Suthar MS, Neish AS, Dhodapkar MV, Dhodapkar KM. Azeem MI, et al. Among authors: switchenko jm. Blood Cancer Discov. 2023 Mar 1;4(2):106-117. doi: 10.1158/2643-3230.BCD-22-0173. Blood Cancer Discov. 2023. PMID: 36511813 Free PMC article.
Antibody binding and neutralization of live SARS-CoV-2 variants including BA.4/5 following booster vaccination of patients with B-cell malignancies.
Chang A, Akhtar A, Lai L, Orellana-Noia VM, Linderman SL, McCook-Veal AA, Switchenko JM, Saini M, Valanparambil RM, Blum KA, Allen PB, Lechowicz MJ, Romancik JT, Ayers A, Leal A, O'Leary CB, Churnetski MC, Baird K, Kives M, Wrammert J, Nooka AK, Koff JL, Dhodapkar MV, Suthar MS, Cohen JB, Ahmed R. Chang A, et al. Among authors: switchenko jm. Cancer Res Commun. 2022 Dec;2(12):1684-1692. doi: 10.1158/2767-9764.crc-22-0471. Cancer Res Commun. 2022. PMID: 36644323 Free PMC article.
Shifting Sociodemographic Characteristics of a Phase I Clinical Trial Population at an NCI-Designated Comprehensive Cancer Center in the Southeast.
Lalonde CS, Switchenko JM, Behera M, Bilen MA, Owonikoko TK, Kaufman JL, Nooka AK, Lewis CM, Hitron E, Collins H, Judson EC, Alese OB, Donald Harvey R, Carlisle JW. Lalonde CS, et al. Among authors: switchenko jm. Oncologist. 2023 Dec 11;28(12):1055-1063. doi: 10.1093/oncolo/oyad181. Oncologist. 2023. PMID: 37418599 Free PMC article. Clinical Trial.
Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy.
Robinson MH, Villa NY, Jaye DL, Nooka AK, Duffy A, McCachren SS, Manalo J, Switchenko JM, Barnes S, Potdar S, Azeem MI, Horvat AA, Parihar VC, Gong J, Liang Y, Smith GH, Gupta VA, Boise LH, Kaufman JL, Hofmeister CC, Joseph NS, Lonial S, Dhodapkar KM, Dhodapkar MV. Robinson MH, et al. Among authors: switchenko jm. J Clin Invest. 2023 Aug 1;133(15):e167629. doi: 10.1172/JCI167629. J Clin Invest. 2023. PMID: 37526080 Free PMC article.
228 results